Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M658Revenue $M27.2Net Margin (%)0Z-Score0
Enterprise Value $M588EPS $0Operating Margin %0F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %0Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M0ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with TSRX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TSRXJean-Marie Eveillard 2013-09-30 Sold Out -0.04%$8.19 - $14.1
($12.39)
$ 13.6410%Sold Out0
TSRXJean-Marie Eveillard 2013-03-31 Add0.02%$4.78 - $7
($5.65)
$ 13.64141%Add 69.6%1,794,780
TSRXJean-Marie Eveillard 2012-06-30 Add0.01%$5.02 - $5.99
($5.25)
$ 13.64160%Add 102.26%1,058,212
TSRXJean-Marie Eveillard 2012-03-31 Buy 0.01%$4.8 - $6.78
($5.08)
$ 13.64168%New holding, 523186 sh.523,186
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TSRX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


TSRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Finn JohnChief Scientific Officer 2013-07-22Sell1,000$12.112.73 view
Finn JohnChief Scientific Officer 2013-07-15Sell3,500$10.5529.29 view
Finn JohnChief Scientific Officer 2013-07-12Sell6,500$9.8139.04 view
MORNEAU MICHAELVP Finance & CAO 2013-07-11Sell20,000$9.7539.9 view
Prokocimer PhilippeChief Medical Officer 2013-07-01Sell2,000$8.1467.57 view
Bartizal KenChief Development Officer 2013-07-01Sell2,000$8.1467.57 view
Finn JohnChief Scientific Officer 2013-06-12Sell3,000$9.0850.22 view
Finn JohnChief Scientific Officer 2013-06-11Sell1,000$8.9452.57 view
Bartizal KenChief Development Officer 2013-06-04Sell2,000$7.972.66 view
Prokocimer PhilippeChief Medical Officer 2013-06-03Sell2,000$7.7576 view

Press Releases about TSRX :

    Quarterly/Annual Reports about TSRX:

    News about TSRX:

    Articles On GuruFocus.com
    comment on TSRX Mar 15 2013 
    comment on TSRX Mar 15 2013 

    More From Other Websites
    Former CEO of Trius Therapeutics Publishes New Blog Entitled “FDA Drug Approvals: Congress Giveth... Oct 08 2013
    Regeneron (REGN) a Biotech Success Story: Growth and Opportunities from Ocular Drug and a... Sep 19 2013
    TRIUS THERAPEUTICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Sep 11 2013
    Cubist Pharmaceuticals Completes Acquisition of Trius Therapeutics Sep 11 2013
    Cubist Pharmaceuticals Announces Results of Tender Offer for Outstanding Shares of Trius... Sep 11 2013
    Scientific Conferences Create Buzz And Move Biotech Stocks: Michael King Sep 06 2013
    Cubist Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Trius Aug 29 2013
    Trius Therapeutics price target raised to $15 from $10 at Leerink Aug 16 2013
    TRIUS THERAPEUTICS INC Financials Aug 15 2013
    Cubist Pharmaceuticals' Strategic Acquisitions Are Great For Investors Aug 14 2013
    Upcoming Catalyst Could Spark Another Run For Insmed Aug 14 2013
    TRIUS THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Aug 07 2013
    TRIUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 06 2013
    SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Trius Therapeutics,... Aug 06 2013
    The Best- And Worst-Performing Biotech Stocks July 26 To August 2 Aug 04 2013

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide